Brief: Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease
May 13 (Reuters) - Absci Corp ABSI.O: ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF ABS-101, A POTENTIAL BEST-IN-CLASS ANTI-TL1A ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2025 ABSCI CORP - ABS-101 SHOWS HIGH POTENCY AND QUARTERLY DOSING POTENTIAL Source text: ID:nGNX5RX86F Further company coverage: ABSI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave